Penn Pharma
Penn Pharma has successfully completed the first batch of coated tablets in its new contained manufacturing operation. Less than a year after announcing the ambitious programme to build the new facility at Penn Pharma’s South Wales, UK, base, this marks a major achievement.
The new 1,395 m2 site has been built for the clinical and commercial manufacture of tablets and capsules and will allow Penn Pharma to build on its heritage and varied services.
The marketplace has seen growth in the number of highly potent compounds requiring solid dosage development and with this new facility, Penn Pharma is ideally positioned to address the formulation and both clinical and commercial manufacturing needs of its clients.
Penn Pharma Chief Executive Officer, Richard Yarwood, said: “It is a monumental day for Penn Pharma, in less than one year we have built a world-class facility for contained manufacturing and produced our first batch of coated tablets. This gives our customers even greater confidence that Penn Pharma can meet the challenging timelines they require to get their products to market.”
Penn Pharma Chief Operating Officer, Mark Dean-Netscher, said: “This success is the result of hard work and determination to get us to this stage in such a short space of time. A facility of this complex nature was a tight build in the timeframe but we have demonstrated that when Penn Pharma commits to something, we always deliver.”
Penn Pharma, +44 1495 711 222, www.pennpharm.com.